When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit?
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Analysts Hunt for Undervalued Biotech Stocks
Express News | EF Hutton Initiates Coverage On Citius Pharma With Buy Rating, Announces Price Target of $6
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Are Analysts Optimistic?
Biopharma Stocks Transformative Innovation for the Future of Health
Express News | Citius Pharmaceuticals Announced Expected Milestones in H2 2024
Express News | Citius Pharmaceuticals: Preparing for Near-Term Commercialization of Lymphir IF Approved
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
Sidoti Events, LLC's Virtual June Small-Cap Conference
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Citius Pharma Analyst Ratings
Buy Rating Reaffirmed for Citius Pharmaceuticals Amid Strong Clinical Trial Results and Growth Prospects
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Analysts Are Bullish on Top Healthcare Stocks: Citius Pharmaceuticals (CTXR), Actinium Pharmaceuticals (ATNM)
Citius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream Infections
Express News | Citius Pharmaceuticals Shares up 10.5% After Co's Anti-Infective Drug Succeeds in Late-Stage Study
Citius Gains as Late-stage Trial for Mino-Lok Succeeds
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Express News | Citius Pharmaceuticals Shares Are Trading Higher After the Company's Phase 3 Trial of Mino-Lok Met Primary and Secondary Endpoints